scPharmaceuticals Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q4 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: scPharmaceuticals Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q4 2024.
scPharmaceuticals Inc. Debt-to-equity for the quarter ending December 31, 2024 was 384 %, a 300% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q4 2024	384	+288	+300%	Dec 31, 2024
Q3 2024	257	+176	+218%	Sep 30, 2024
Q2 2024	187	+116	+164%	Jun 30, 2024
Q1 2024	126	+62.1	+98%	Mar 31, 2024
Q4 2023	96	+40.5	+73.1%	Dec 31, 2023
Q3 2023	80.9	+36.9	+83.9%	Sep 30, 2023
Q2 2023	70.6	+29.9	+73.5%	Jun 30, 2023
Q1 2023	63.4	+25.1	+65.7%	Mar 31, 2023
Q4 2022	55.5	+19	+52.1%	Dec 31, 2022
Q3 2022	44	+9.27	+26.7%	Sep 30, 2022
Q2 2022	40.7	+8.02	+24.6%	Jun 30, 2022
Q1 2022	38.3	+7.97	+26.3%	Mar 31, 2022
Q4 2021	36.5	+4.1	+12.7%	Dec 31, 2021
Q3 2021	34.7	-0.71	-2%	Sep 30, 2021
Q2 2021	32.7	-7.72	-19.1%	Jun 30, 2021
Q1 2021	30.3	-13.6	-31.1%	Mar 31, 2021
Q4 2020	32.4	-5.42	-14.3%	Dec 31, 2020
Q3 2020	35.4	+5.5	+18.4%	Sep 30, 2020
Q2 2020	40.4	+17.5	+76.7%	Jun 30, 2020
Q1 2020	43.9	+24	+120%	Mar 31, 2020
Q4 2019	37.8	+19.9	+111%	Dec 31, 2019
Q3 2019	29.9	+13	+76.9%	Sep 30, 2019
Q2 2019	22.8			Jun 30, 2019
Q1 2019	19.9			Mar 31, 2019
Q4 2018	17.9			Dec 31, 2018
Q3 2018	16.9			Sep 30, 2018

* An asterisk sign (*) next to the value indicates that the value is likely invalid.